Why Erasca, Inc.’s (ERAS) Stock Is Down 5.46%
As of Wednesday, July 29, Erasca, Inc.’s ERAS share price has dipped by 5.46%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Commentary & Analysis
Why Erasca, Inc.’s (ERAS) Stock Is Down 5.93%
As of Thursday, July 16, Erasca, Inc.’s ERAS share price has dipped by 5.93%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Erasca, Inc.’s (ERAS) Stock Is Up 5.64%
As of Wednesday, July 15, Erasca, Inc.’s ERAS share price has surged by 5.64%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Erasca, Inc.’s (ERAS) Stock Is Up 7.23%
As of Tuesday, July 14, Erasca, Inc.’s ERAS share price has surged by 7.23%, which has investors questioning if this is right time to sell.Michael Rose
Why Erasca, Inc.’s (ERAS) Stock Is Down 5.27%
As of Friday, July 10, Erasca, Inc.’s ERAS share price has dipped by 5.27%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | ERAS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6,300.4 | $252.6 | 71% |
|
| Shares Out (Mil) | 304.3 | 52.3 | 83% |
|
| Institutional Ownership | 88.2% | 92.1% | 56% |
|
| Float (Mil) | 276.4 | 40.2 | 79% |
|
| Beta | 0.68 | 0.95 | 39% |
|
| Avg Daily Volume (000s) | 3,415 | 455 | 89% |
|
| Price Change (52-week) |
1,071% | 52.9% | 100% |
|
| Growth | ERAS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (4.1%) | (9.9%) | 35% |
|
| EPS (5yr) | 38.1% | 16.0% | 87 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (59.0%) | (15.6%) | 4% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 9 | 9 | |
| Current EPS | ($0.112) | ($0.953) | ($0.553) | |
| Month Ago EPS | ($0.115) | ($0.966) | ($0.575) | |
| # Rev Up | 3 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.107) | ($0.565) | ($0.564) | |
| Year/Year Chg | (81.4%) | 117.1% | 53.5% | |
| Financials | ERAS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($277) | ($43) | 5% |
|
| EPS (TTM) | ($0.959) | ($1.600) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | ($91) | ($31) | 6% |
|
| Net Cash Flow (TTM) (Mil) | ($23) | $5 | 25% |
|
| Long-Term Debt (Q1) (Mil) | $41 | $5 | 37% |
|
| Enterprise Value (Q1) (Mil) | $2,866 | $180 | 54% |
|
| Valuation | ERAS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 14.29 | 2.56 | 93% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ERAS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (59.4%) | (49.8%) | 10% |
|
| ROE | (69.9%) | (55.5%) | 12% |
|
| Liabilities to Assets | 14.7% | 30.3% | 9% |
|
| F-Score | 2 | 3 | 7% |
|
Erasca, Inc. did not pass any screens on 7/31/2026.
